The 16.6-month median OS in heavily pre-treated MBC is a strong signal for a Phase 3 asset. Monitor the ASCO presentations (May 30–June 1) for additional detail and any unblinded Phase 3 data. The stock may see volatility around the conference dates.
Price Chart
Executive Summary
BriaCell announced positive Phase 2 survival data for Bria-IMT in heavily pre-treated metastatic breast cancer, with median overall survival of 16.6 months for the Phase 3 formulation and 52% 12-month survival. Quality-of-life data from the ongoing Phase 3 study showed preserved global health with minimal toxicity, supporting potential home self-administration. The data will be presented at the 2026 ASCO Annual Meeting.
Key Facts
- Median overall survival of 16.6 months for the Phase 3 formulation in heavily pre-treated MBC patients (median 6 prior therapies)
- 52% 12-month survival rate for the Phase 3 formulation; 44% at 12 months and 26% at 24 months overall
- No treatment-related discontinuations and no unexpected safety signals in the Phase 2 study
- Quality-of-life data from the ongoing Phase 3 study showed stable global health and key functional domains with minimal toxicity
- Biomarker analyses confirmed DTH positivity and lower baseline CTC levels as predictors of better survival
- Data to be presented at the 2026 ASCO Annual Meeting (May 29–June 2, 2026)
Financial Impact
No financial data provided; BriaCell is a clinical-stage biotech with no approved products or revenue. The positive Phase 2 survival data and QOL results could support regulatory advancement and potential partnership interest.
Risk Factors
- Phase 3 study remains blinded; unblinding at 144 mortalities could yield different results
- No revenue or near-term commercialization path; cash burn risk for a clinical-stage company
- Small Phase 2 sample size (n=32) limits statistical reliability
- Competition from approved ADCs, CPIs, and CDK4/6 inhibitors in MBC
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers